Century Therapeutics, Inc. (IPSC) Stock Grade

About Century Therapeutics, Inc.'s fundamentals

Century Therapeutics is a biotechnology company with a market capitalization of $86.1 million that reported exceptional revenue growth of 1,556.8% year-over-year, indicating rapid commercial traction or scaling of operations. However, the company is currently unprofitable, with a negative net margin of -8.8% and a reported net loss in its latest annual statement, reflecting typical early-stage biotech dynamics where growth investments precede profitability. The company does not pay a dividend, which is consistent with reinvesting available resources into research and development activities.